Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 5945 record(s)

Req # A-2020-001509

Adverse Drug Reaction (ADR) for CLOPIDOGREL BISULFATE. Report number: E2B_03245485.

Organization: Health Canada

43 page(s)
February 2024

Req # A-2020-001530

Adverse Drug Reactions (ADRs). Report numbers: E2B_03072268, E2B_03073424, E2B_03073540, E2B_03073550, E2B_03073575, E2B_03073581, E2B_03073710, E2B_03073853, E2B_03074304, E2B_03074380, E2B_03074429, E2B_03074463, E2B_03074464, E2B_03074625, E2B_03074640, E2B_03074799, E2B_03074805, E2B_03075045, E2B_03075297, E2B_03075303.

Organization: Health Canada

382 page(s)
February 2024

Req # A-2020-001561

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-075497-407.

Organization: Health Canada

97 page(s)
February 2024

Req # A-2020-001579

Adverse Drug Reactions (ADRs). Report numbers: E2B_03239485, E2B_03239609, E2B_03239877, E2B_03240311, E2B_03241189, E2B_03241585, E2B_03245204, E2B_03246534, E2B_03246726, E2B_03246754, E2B_03247430, E2B_03247647, E2B_03248630, E2B_03248901, E2B_03249058, E2B_03249595, E2B_03249643, E2B_03249643, E2B_03250737, E2B_03250766, E2B_03251864.

Organization: Health Canada

469 page(s)
February 2024

Req # A-2020-001664

Adverse Drug Reactions (ADRs). Report numbers: E2B_02764699, E2B_02778990, E2B_02796241, E2B_02796244, E2B_02796251, E2B_02796257, E2B_02796260, E2B_02796261, E2B_02799214, E2B_01356283, E2B_01308774, 000735698.

Organization: Health Canada

264 page(s)
February 2024

Req # A-2020-001850

Adverse Drug Reactions (ADRs). Report numbers: E2B_03488338, E2B_03488350, E2B_03488353, E2B_03506446, E2B_03508146, E2B_03514010, E2B_03521134, E2B_02235122, E2B_03494748, E2B_03513051, 000922944, 000923357, 000923359, 000923514, 000923894, 000924233, 000924562, 000925983, 000926516, 000926880.

Organization: Health Canada

273 page(s)
February 2024

Req # A-2021-001082

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-106962-511, Possible Priorities for the Deputy Minister Community of Science and Technology.

Organization: Health Canada

6 page(s)
February 2024

Req # A-2021-001086

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-107154-405.

Organization: Health Canada

17 page(s)
February 2024

Req # A-2021-001267

Adverse Drug Reactions (ADRs). Report numbers: E2B_03758004, 943920, 930417, 936560, E2B_03811824, E2B_03923360, E2B_03841105, E2B_03821244, E2B_03866568, E2B_03844466, E2B_03840754.

Organization: Health Canada

233 page(s)
February 2024

Req # A-2021-001277

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-114482-884.

Organization: Health Canada

9 page(s)
February 2024
Date modified: